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Abstract 10 
Introduction and objectives A large proportion of patients with non-ST-segment 11 
elevation acute coronary syndrome (NSTE-ACS) are initially managed medically 12 
and do not undergo coronary revascularization during or immediately after the 13 
index event. The aim was to explore the clinical pathways leading to medical 14 
management in NSTE-ACS patients, and their influence on prognosis. 15 
Methods Patient characteristics, pathways leading to medical management and 2-16 
year outcomes were recorded in a prospective cohort of 5591 NSTE-ACS patients 17 
enrolled in 555 hospitals in 20 countries across Europe and Latin America. Cox 18 
models were used to assess the impact of hospital management on post-discharge 19 
mortality.  20 
Results Medical management was the selected strategy in 2306 (41.2%) patients, 21 
of whom 669 (29%) showed significant coronary artery disease (CAD), 451 22 
(19.6%) non-significant disease, and 1186 (51.4%) did not undergo coronary 23 
angiography. Medically managed patients were older with higher risk features than 24 
revascularized patients. Two-year mortality was higher in medically managed than 25 
revascularized patients (11.0% vs 4.4%, P < .001), with higher mortality rates in 26 
patients who did not undergo angiography (14.6%), and those with significant CAD 27 
(9.3%). Compared with revascularized patients, risk-adjusted mortality was highest 28 
for patients who did not undergo angiography (hazard ratio 1.81; 95% confidence 29 
interval [CI], 1.23-2.65), or were not revascularized in the presence of significant 30 
CAD (hazard ratio 1.90; 95% CI, 1.23-2.95). 31 
  
3 
Conclusions Medically managed NSTE-ACS patients represent a heterogeneous 32 
population with distinct risk profiles and outcomes. These differences should be 33 
considered when designing future studies in this population. 34 
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: 35 
NCT01171404. 36 
Key Words: coronary disease, angiography, prognosis 37 
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Abbreviations 39 
EPICOR long-tErm follow-up of antithrombotic management Patterns In acute 40 
CORonary syndrome patients 41 
CAD  coronary artery disease 42 
CAG  coronary angiography 43 
CR  coronary revascularization 44 
MM  medical management 45 
NSTE-ACS  non-ST-segment elevation acute coronary syndromes 46 
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Introduction 47 
 An invasive management strategy is recommended for the majority of 48 
patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS).1-49 
3 Nevertheless, a large proportion of NSTE-ACS patients are initially managed 50 
medically; that is, they do not undergo coronary revascularization during or 51 
immediately after the index admission.4-6 This observation has triggered studies 52 
designed to evaluate specific therapeutic approaches for these patients.7-13 53 
However, patients with NSTE-ACS may be selected for medical management for a 54 
number of different reasons, and we hypothesized that patient profiles and 55 
outcomes may vary accordingly.  56 
The aims of this analysis were to study rates of use of the different 57 
management strategies for NSTE-ACS in real-world practice from an international 58 
perspective, the main clinical pathways that  lead to the non-use of coronary 59 
revascularization, and the relationship between these pathways and post-60 
discharge outcomes. 61 
 62 
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Methods 63 
Study design 64 
 EPICOR (long-tErm follow-up of antithrombotic management Patterns In 65 
acute CORonary syndrome patients) is a prospective, international, observational, 66 
real-life practice, cohort study. The rationale, design, definitions, site selection, and 67 
baseline patient characteristics have been published previously.14-16 Briefly, 10 568 68 
patients hospitalized for an ACS, with or without ST-segment elevation, within 24 69 
hours of symptom onset and who survived until hospital discharge were enrolled in 70 
555 hospitals in 20 countries in Northern, Southern, and Eastern Europe and 71 
Latin America between September 2010 and March 2011. Patients were excluded 72 
from the study if they had ‘secondary’ ACS, any condition or circumstance that may 73 
limit completion of follow-up, serious comorbidities considered likely to limit life 74 
expectancy to less than 6 months, and previous enrolment in EPICOR or another 75 
clinical trial. All patients gave informed consent. Medical treatments for ACS, 76 
diagnostic and therapeutic procedures, and clinical events during the acute phase 77 
(pre- and in-hospital) were recorded using electronic case report forms. Patients 78 
were followed up by telephone calls up to 2 years after hospital discharge. Vital 79 
status, hospitalizations, cardiovascular and bleeding events, and changes in 80 
medication were recorded for each call. 81 
Definitions used in EPICOR have been presented elsewhere.14, 16 A 82 
diagnosis of non-ST-segment elevation myocardial infarction required the presence 83 
of chest pain/discomfort, lack of persistent ST-segment elevation, left bundle 84 
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branch block or intraventricular conduction disturbances, and elevation of cardiac 85 
biomarkers (CK-MB and troponins) with at least 1 value above the 99th percentile 86 
of the upper reference limit. Unstable angina was defined as the presence of 87 
angina symptoms at rest or on minimal exercise, and transient ST-T changes, and 88 
no significant increase in biomarkers of necrosis but objective evidence of ischemia 89 
by non-invasive imaging or significant coronary stenosis at angiography. 90 
Cardiovascular events included myocardial infarction, heart failure, arrhythmia, 91 
unstable angina, ischemic stroke, and transient ischemic attack. Bleeding events 92 
included all kinds of bleeds. 93 
 94 
Management strategies 95 
 Two management strategies were defined for patients with NSTE-ACS: 96 
“Coronary Revascularization” (CR), which included patients who underwent any 97 
kind of coronary revascularization (either percutaneous or surgical) during index 98 
admission and “Medical Management” (MM), for those discharged without CR. 99 
According to the reasons for MM, 3 subgroups were pre-defined: (i) patients who 100 
did not undergo diagnostic coronary angiography (CAG-); (ii) patients who 101 
underwent CAG and had significant (at least 1 stenosis >50% in 1 coronary artery) 102 
coronary artery disease (CAD) but did not undergo coronary revascularization 103 
(CAG+, CAD+), and (iii) patients who underwent angiography and had no 104 
significant CAD (CAG+, CAD-).17 105 
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Statistical analysis 106 
 Baseline characteristics, hospital management, and in-hospital outcomes for 107 
patients with NSTE-ACS were compared according to initial management strategy. 108 
Comparisons were made between CR and MM or across the 3 MM subgroups 109 
using Chi-square tests. In a second step, we investigated the independent 110 
predictors of undergoing angiography or selection for MM. We used univariate 111 
logistic regression models to assess any association between angiography or MM 112 
and individual covariates. To investigate which were the strongest independent 113 
predictors, we used multivariate logistic regression. We forced the inclusion of 114 
geographical region (Northern Europe, Eastern Europe, Southern Europe and Latin 115 
America) and type of hospital (regional, non-university general, university general 116 
and private) into the model. Additionally, we fitted a random-effect at the hospital 117 
level to account for within-hospital clustering of events. We used a forward 118 
stepwise variable selection with a P-value cut-off of 0.05 to select a final model. 119 
Finally, the impact of MM on 2-year outcomes was studied. Comparisons of clinical 120 
outcome rates (mortality, cardiovascular events, and bleeding events) during 121 
follow-up between the management groups were done by fitting a Cox proportional 122 
hazards model for time to death or time to first event, censored at 2 years post-123 
discharge.  In our minimally adjusted Cox models, we adjusted for age, sex, 124 
geographical region, type of hospital (as described above), and a random-effect 125 
(shared frailty) term at the hospital level. In our fully adjusted models, we 126 
additionally adjusted risk factors associated with 1-year mortality identified from our 127 
previous publication.18 128 
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Results 129 
Management strategies for patients with NSTE-ACS 130 
 A total of 5625 NSTE-ACS patients were enrolled at hospital discharge. 131 
Data on in-hospital management strategies were available for all except 34 (0.7%) 132 
of these. Of the remaining 5591 patients, 4405 (78.8%) underwent CAG (Figure 1). 133 
Of these, 3954 patients (70.7%) had CAD, and 3285 (58.8%) underwent CR in 134 
hospital. Therefore, a total of 2306 patients (41.2%) were medically managed. The 135 
majority of MM patients (51.4%, n = 1186) did not undergo CAG during 136 
hospitalization (21.2% of total population), 451 (19.6% of MM, 8.1% of total 137 
population) lacked significant CAD, and 669 (29.0% of MM, 12.0% of total 138 
population) had significant CAD, but CR was not attempted (Figure 1). 139 
Patients who received MM were older and less likely to present with non-140 
ST-segment elevation myocardial infarction, but more often had prior 141 
cardiovascular diseases, comorbidities, and cardiovascular medications (Table 1). 142 
They also had more severe cardiac disease (Table 1). When characteristics were 143 
compared across the 3 pre-defined subgroups of MM patients, significant 144 
differences were found again, with a gradient from younger age and lower 145 
comorbidity and cardiovascular burden among CAG+ CAD- patients to older and 146 
sicker patients among CAG- patients. Significant regional differences were found in 147 
the rate of MM (data not shown). 148 
The most important independent predictor of undergoing CAG during index 149 
hospitalization (Table S1 in the online-only Data Supplement) was the presence of 150 
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catheterization laboratory in the hospital (OR 46.8, 95%CI, 22.4-97.6). NSTEMI 151 
(OR, 1.72 95% CI 1.24-2.38) was associated with a higher probability of 152 
undergoing coronary angiography compared with unstable angina as well as prior 153 
myocardial infarction (OR, 1.58; 95% CI, 1.07 to 2.32), while age >75 years (OR, 154 
0.38, 95% CI, 0.28-0.53), current smoking (OR, 0.67; 95% CI, 0.51-0.88), 155 
hemoglobin levels <13 g/dL (OR, 0.65; 95% CI, 0.48 to 0.78), prior myocardial 156 
infarction (or 0.56; 95%CI, 0.39-0.67), prior coronary artery bypass graft surgery 157 
(OR, 0.60; 95%CI, 0.38-0.94), prior heart failure (OR, 0.30; 95%CI, 0.19-0.49), and 158 
being on angiotensin-converting enzyme inhibitors at admission (OR, 0.70; 95%CI, 159 
0.53 to 0.92) were associated with lower probabilities. Patients from Latin America 160 
(OR 0.04; 95% CI 0.02-0.11) and Eastern Europe (OR, 0.15; 95%CI, 0.06-0.35) 161 
presented a lower probability of undergoing CAG than patients from Northern 162 
Europe. 163 
Independent predictors of not undergoing CR (Table S2 in the online-only 164 
Data Supplement) among those who underwent CAG and had significant CAD 165 
were prior cardiovascular disease (OR, 0.53; 95%CI, 0.42-0.67), prior coronary 166 
artery bypass graft (OR, 0.45; 95%CI, 0.32-0.63), age >75 years (OR, 0.73; 167 
95%CI, 0.55-0.98) and serum creatinine >1.2 mg/dl (OR, 0.76; 95%CI, 0.58-0.99) 168 
were marginally associated with lower probabilities while male patients showed  a 169 
higher probability (OR, 1.34; 95%CI 1.04-1.72) . Patients from Latin America (OR 170 
0.29; 95% CI 0.18-0.48) and Eastern Europe (OR, 0.50; 95%CI, 0.33-0.87) 171 
presented a lower probability of undergoing revascularization after CAG than 172 
patients from Northern Europe. Admission to private hospitals was associated to 173 
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an increased probability of being revascularised during hospitalization (OR, 2.19; 174 
95%CI 1.14 to 4.20) 175 
 176 
In-hospital diagnostic and therapeutic procedures, and medical treatments 177 
by management strategy 178 
 In general, MM patients less frequently received diagnostic and therapeutic 179 
procedures during hospitalization compared with CR patients (Table 2). Although 180 
all antithrombotic drugs and most cardiovascular preventative treatments were 181 
prescribed in the majority of patients, MM patients were less likely to receive them 182 
in hospital. Among those who underwent CAG, multivessel disease was 183 
significantly more frequent in CR than MM patients as a whole but not in the 184 
subgroup of MM patients with significant CAD. Interestingly, the results of coronary 185 
angiography triggered small changes in antiplatelet drugs both in CR and MM 186 
patients, with the exception of clopidogrel, which was withdrawn in a substantial 187 
proportion of MM patients at discharge (Table 2). 188 
Outcomes by management strategy 189 
Medically managed patients had a greater incidence of in-hospital 190 
cardiovascular complications, mainly heart failure and atrial fibrillation, particularly 191 
among patients who did not undergo CAG (Table 3). The 2-year post discharge all-192 
cause mortality rate was 7.0% in the whole cohort, with significant differences 193 
between CR and MM patients (4.4% vs  11%; P < 0.001) (Table 3, Figure 2A). A 194 
gradient in 2-year mortality was also found among MM patients, with patients who 195 
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did not receive CAG showing the highest mortality (14.6%) and those without 196 
significant obstructive CAD the lowest (4.1%). Cardiovascular event rates at 2 197 
years, including myocardial infarction, heart failure, arrhythmia, unstable angina, 198 
ischemic stroke, and transient ischemic attack, were also significantly higher in MM 199 
compared with CR patients (15.4% vs 9.6%, P < 0.001), and were highest in those 200 
who did not receive CAG (17.4%) (Figure 2B). In contrast, bleeding events were 201 
numerically but not significantly lower in MM versus CR patients (3.4% vs 4.6%, P 202 
= 0.06) (Figure 2C). Among the MM subgroups, the difference in bleeding event 203 
rates was not significant, but appeared lowest in those who underwent CAG and 204 
had no significant CAD. Using 70% stenosis as the cut-off point for CAD+ did not 205 
significantly change the results (data not shown). Compared with the results for the 206 
50% cut-off point, there was a slight increase in mortality rate in both CAG+CAD+ 207 
and CAG+CAD- groups, as they were both composed of higher risk patients, with a 208 
small change in mortality gradient between the groups. Excluding the 190 patients 209 
who underwent revascularization after discharge (including 32 within the first 210 
month) from the analyses, no relevant differences were found in patterns of 211 
mortality or other event rates. 212 
 Lack of CAG was found to be an independent predictor of 2-year mortality, 213 
adjusted for age, gender, and post-discharge mortality predictors as previously 214 
described in the EPICOR cohort18 (hazard ratio , 1.81; 95% confidence interval, 215 
1.23-2.65, P < 0.001). Among patients who underwent CAG, MM patients with 216 
significant CAD had an increased adjusted mortality risk (hazard ratio, 1.90; 95% 217 
confidence interval, 1.23-2.95, P < 0.001), while those without significant CAD did 218 
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not (hazard ratio, 0.68; 95% confidence interval, 0.20-2.21, P < 0.001) (Table S3 in 219 
the online-only Data Supplement). 220 
 221 
Discussion  222 
 The results of this large international cohort study can help us to understand 223 
the heterogeneity of patients with NSTE-ACS, the main clinical pathways leading to 224 
medical management, and its influence on prognosis. Our observations also allow 225 
us to estimate post-discharge event rates in relation to these pathways in a large 226 
cohort of unselected patients surviving NSTE-ACS. This information can be 227 
particularly helpful for risk stratification, clinical follow-up planning, and designing 228 
future studies in this field. 229 
Patients surviving ACS are at high risk of subsequent cardiovascular events, 230 
even if optimally treated.19 Despite recommendations by the main European 231 
guidelines,1, 2 less than 60% of patients undergo CR during hospitalization for 232 
NSTE-ACS. This is clinically relevant given the abundance of data coming from 233 
randomized trials13, 20, 21 and observational studies22 suggesting an improvement in 234 
mid- and long-term prognosis for patients with NSTE-ACS managed invasively. In 235 
our study, the most frequent clinical situation associated with MM is lack of CAG 236 
during hospitalization, which accounts for roughly half of MM cases. Our study is 237 
consistent with previous studies using similar analytical methods insofar as older 238 
and sicker patients are more often MM while younger and lower risk patients 239 
consistently receive more aggressive treatment. This is also true among subgroups 240 
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of MM patients, as those not undergoing CAG show the highest risk profile. Similar 241 
findings were reported in an analysis from the French Registry of Acute ST-242 
Elevation or Non-ST-Elevation Myocardial Infarction (FAST-MI), in which MM 243 
patients with non-ST-segment elevation myocardial infarction who did not undergo 244 
CAG had a higher 5-year mortality rate than those who did, even compared with 245 
CAG+ patients with multivessel disease.23 Moreover, our findings are consistent 246 
with the risk paradox found in several national and international registries,23-27 with 247 
a gradient in age, cardiovascular burden, and comorbidities between 248 
revascularized patients, patients undergoing CAG but not CR and, finally, those not 249 
receiving CAG. Although selection bias may partially explain the higher risk 250 
observed in MM patients, CR remains independently associated with lower 2-year 251 
mortality risk in our population after adjustment for all factors associated with post-252 
discharge mortality in a previously developed predictive model.18   253 
While CAG per se is unlikely to provide any benefit, it has been suggested 254 
that patient selection (ie, whether or not to perform angiography) plays a crucial 255 
role.28 In the EPICOR study, NSTE-ACS patients who did not undergo CAG were 256 
more likely to be older, with unstable angina rather than non-ST-segment elevation 257 
myocardial infarction, and to have hypertension or diabetes. In the TaRgeted 258 
platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute 259 
Coronary Syndromes (TRILOGY ACS) trial, the most frequent reasons for not 260 
undergoing CAG were patient refusal, lack of on-site facilities, and either 261 
unsuitable coronary anatomy or other contraindications.10 Non-catheterized 262 
patients were also more likely to be older, female, and to have a diagnosis of 263 
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unstable angina rather than non-ST-segment elevation myocardial infarction, and 264 
less previous coronary intervention. In a retrospective analysis from the TRILOGY 265 
ACS trial, NSTE-ACS patients who did not undergo angiography also had 266 
significantly poorer outcomes compared with those who did: at 30 months, 267 
cardiovascular death rates were 8.2% and 4.7%, respectively, with all-cause death 268 
rates of 9.6% and 5.8%.7 In EPICOR as in other studies,29 lack of immediate 269 
access to coronary intervention facilities was one of the most important reasons for 270 
initial conservative management. This is true despite the fact that transfers 271 
between hospitals and reasons for transfer were recorded in EPICOR.30 272 
 The regional differences in the probability of undergoing coronary 273 
angiography and coronary revascularization as well as the increased probability of 274 
undergoing revascularization are worth mentioning. These are probably explained 275 
largely by differences in resources, insurance level and care access opportunities, 276 
procedural cost for patients and reimbursement.    277 
Limitations 278 
 This study is based on registry data and, therefore, subject to the limitations 279 
of observational studies, ie, potential bias and confounding. The role of patient 280 
preferences in the decision to undergo CAG and CR was not recorded, and this 281 
may have had an additional influence on the outcomes that could not be 282 
measured. The analysis of only hospital procedures excludes cases in which 283 
scheduled CAG or CR might have been performed. However, when we used wider 284 
time frames for CR  – 10 days (as in TRILOGY ACS) and 30 days – no significant 285 
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changes in our results were found, confirming the consistence of our findings. As 286 
mentioned previously, although our multivariable analysis included a rigorous 287 
adjustment using a previously developed model for mortality prediction,18 288 
unmeasured confounders, such as known CAD not amenable for CR, dementia, 289 
too sick for other medical reasons, or patient preferences, could have affected the 290 
apparent protective role of CAG and CR. In addition, clinical events during follow-291 
up were not centrally adjudicated. Finally, although we attempted to show 292 
representative examples of real-life practice in each country, by careful selection of 293 
local centers, caution for generalizing the results is warranted. 294 
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Conclusions  295 
 Medically managed patients with NSTE-ACS constitute a heterogeneous 296 
group according to the clinical pathways leading to non-use of CAG or CR. 297 
Compared with CR patients, those who do not undergo CAG during hospitalization 298 
are older, and present with greater comorbidity. They also have the highest 299 
adjusted mortality risk after discharge, followed by those not revascularized despite 300 
significant CAD. Therefore, the clinical pathways leading to medical management 301 
are clinically relevant and should be taken into consideration in studies addressing 302 
this patient group, given the observed differences in baseline characteristics and 303 
clinical outcomes. Continuing efforts are needed to improve compliance with 304 
guidelines recommendations, particularly for NSTE-ACS patients admitted to 305 
hospitals without a catheterization laboratory. 306 
  307 
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Key points 308 
What is known about the topic?  309 
 Despite guidelines recommendations for an invasive strategy in most patients 310 
with NSTE-ACS, a large proportion of these patients are initially medically 311 
managed 312 
 Different clinical pathways lead to the selection of medical management in 313 
NSTE-ACS patients 314 
 NSTE-ACS patients who do not undergo coronary angiography, and hence do 315 
not undergo coronary revascularization, are at highest risk of cardiovascular 316 
morbidity and mortality in the long-term  317 
What does the study add? 318 
 Medical management is independently associated with higher 2-year adjusted 319 
mortality risk compared with revascularization. 320 
 The different clinical pathways leading to the selection of medical management 321 
in NSTE-ACS patients have an important influence on patient outcomes. 322 
 Therefore, the reasons for medical management should be taken into 323 
consideration in future studies addressing this patient population 324 
 325 
  326 
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Table 1. Baseline characteristics of non-ST-segment elevation acute coronary syndrome patients by management 453 
strategy 454 
 
Coronary 
Revascularization 
n=3285 
58.8% 
Medical 
Management 
n=2306 
41.2% 
P-Value Medical Management 
(CR 
versus 
MM) 
CAG- 
n=1186 
21.2% 
CAG+ 
CAD+ 
n=669 
12.0% 
CAG+ 
CAD- 
n=451 
8.1% 
P-Value 
Diagnosis        
 NSTEMI (n=5591) 2491 
(75.8%) 
1482 
(64.3%) 
<0.0001 725 
(61.1%) 
454 
(67.9%) 
303 
(67.2%) 
0.0051 
 UA (n=5591) 794 
(24.2%) 
824 
(35.7%) 
<0.0001 461 
(38.9%) 
215 
(32.1%) 
148 
(32.8%) 
0.0051 
Basic characteristics        
 Age >75 years (n=5591) 559 
(17.0%) 
553 
(24.0%) 
<0.0001 346 
(29.2%) 
139 
(20.8%) 
68 
(15.1%) 
<0.0001 
 Male (n=5591) 2513 
(76.5%) 
1463 
(63.4%) 
<0.0001 750 
(63.2%) 
484 
(72.3%) 
229 
(50.8%) 
<0.0001 
CV risk factors        
 Hypertension (n=5525) 2084 
(64.3%) 
1603 
(70.2%) 
<0.0001 874 
(74.3%) 
466 
(70.4%) 
263 
(59.1%) 
<0.0001 
 Hypercholesterolemia (n=5373) 1716 1228 0.311 617 399 212 <0.0001 
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(54.2%) (55.6%) (55.0%) (61.8%) (48.1%) 
 Diabetes mellitus (n=5526) 800 
(24.7%) 
705 
(30.9%) 
<0.0001 412 
(35.2%) 
213 
(32.1%) 
80 
(17.9%) 
<0.0001 
 Current smoking (n=5198) 996 
(32.5%) 
851 
(39.9%) 
<0.0001 451 
(41.2%) 
221 
(35.6%) 
179 
(43.0%) 
0.0263 
 Glucose >160 mg/dL (n=4856) 548 
(19.4%) 
475 
(23.4%) 
0.0007 294 
(26.8%) 
136 
(23.4%) 
45 
(12.7%) 
<0.0001 
 Hemoglobin <13 mg/dL (n = 5217) 656 
(21.4%) 
668 
(31.1%) 
<0.0001 401 
(35.5%) 
174 
(28.3%) 
93 
(23.0%) 
<0.0001 
Previous CVD        
 Prior CVD (n=5547) 1372 
(42.1%) 
1288 
(56.3%) 
<0.0001 695 
(58.8%) 
399 
(60.4%) 
194 
(43.4%) 
<0.0001 
 Prior MI (n=5510) 730 
(22.5%) 
728 
(32.1%) 
<0.0001 428 
(36.5%) 
213 
(32.6%) 
87 
(19.6%) 
<0.0001 
 Prior PCI (n=5511) 710 
(21.9%) 
452 
(19.9%) 
0.081 195 
(16.7%) 
165 
(25.2%) 
92 
(20.7%) 
<0.0001 
 Prior CABG (n=5544) 267 
(8.2%) 
264 
(11.5%) 
<0.0001 130 
(11.0%) 
120 
(18.2%) 
14 
(3.1%) 
<0.0001 
 Heart failure (n=5514) 158 
(4.9%) 
259 
(11.4%) 
<0.0001 188 
(16.1%) 
46 
(7.0%) 
2  
(5.6%) 
<0.0001 
 Arial fibrillation (n=5531) 158 
(4.9%) 
210 
(9.2%) 
<0.0001 117 
(10.0%) 
54 
(8.2%) 
39 
(8.8%) 
0.4139 
 TIA/stroke (n=5535) 197 
(6.1%) 
168 
(7.4%) 
0.0548 98 
(8.3%) 
48 
(7.3%) 
22 
(4.9%) 
0.0634 
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 PVD (n=5474) 212 
(6.6%) 
171 
(7.6%) 
0.1396 92 
(8.0%) 
62 
(9.5%) 
17 
(3.8%) 
0.0018 
Chronic kidney disease (n=5591) 151 
(4.6%) 
162 
(7.0%) 
0.0003 110 
(9.3%) 
42 
(6.3%) 
10 
(2.2%) 
<0.0001 
 Serum creatinine >1.2 mg/dL 
(n=5291) 
680 
(21.9%) 
636 
(29.0%) 
<0.0001 361 
(31.7%) 
189 
(29.9%) 
86 
(20.6%) 
<0.0001 
Chronic CV medication        
 Antiplatelets (n=5591) 1425 
(43.4%) 
1179 
(51.1%) 
<0.0001 606 
(51.1%) 
387 
(57.8%) 
186 
(41.2%) 
<0.0001 
 Aspirin (n=5590) 1347 
(41.0%) 
1108 
(48.1%) 
<0.0001 571 
(48.2%) 
365 
(54.6%) 
172 
(38.1%) 
<0.0001 
 Clopidogrel (n=5585) 435 
(13.3%) 
397 
(17.2%) 
<0.0001 211 
(17.8%) 
112 
(16.8%) 
74 
(16.4%) 
0.7445 
 Anticoagulants (n=5591) 122 
(3.7%) 
145 
(6.3%) 
<0.0001 84 
(7.1%) 
34 
(5.1%) 
27 
(6.0%) 
0.2241 
 ACE inhibitors/ARBs (n=5577) 1358  
(41.5%) 
1148  
(49.9%) 
<0.0001 645 
(54.5%) 
316 
(47.4%) 
187 
(41.6%) 
<0.0001 
 Beta-blockers (n=5582) 1208 
(36.9%) 
995 
(43.2%) 
<0.0001 533 
(45.0%) 
303 
(45.3%) 
159 
(35.3%) 
0.0008 
 Statins (n=5573) 1272 
(38.8%) 
948 
(41.3%) 
0.0634 473 
(40.2%) 
301 
(45.0%) 
174 
(38.8%) 
0.0606 
  
28 
ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass graft; CAD, coronary artery 455 
disease; CAG, coronary angiography; CR, coronary revascularization; CV, cardiovascular; CVD, cardiovascular disease; MI, myocardial infarction; 456 
MM, medically managed; NSTE-ACS, non-ST-segment elevation acute coronary syndrome; NSTEMI, non-ST-segment elevation myocardial 457 
infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; TIA, transient ischemic attack; UA, unstable angina. 458 
  459 
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Table 2. Hospital procedures and hospital and discharge treatments by management strategy  460 
 
Coronary 
Revascularization 
n=3285 
58.8% 
Medical 
Management 
n=2306 
41.2% 
P-Value Medical Management  
(CR versus 
MM) 
CAG- 
n=1186  
21.2% 
CAG+ 
CAD+ 
n=669 
12.0% 
CAG+ 
CAD- 
n=451 
8.1% 
P-Value 
Antithrombotic Medications 
       
Aspirin  Initial (n=5591) 
3122 
(95.0%) 
2067  
(89.6%) <0.0001 
1033 
(87.1%) 
629 
(94.0%) 
405 
(89.8%) <0.0001 
 
Discharge 
(n=5586) 
3230 
(98.4%) 
2101 
(91.2%) <0.0001 
1061 
(89.6%) 
635 
(95.1%) 
405 
(89.8%) 0.0001 
Clopidogrel  Initial (n=5591) 
2983 
(90.8%) 
1876 
(81.4%) <0.0001 
959 
(80.9%) 
545 
(81.5%) 
372 
(82.5%) 0.7499 
 
Discharge 
(n=5578) 
2852 
(87.0%) 
1678 
(73.0%) <0.0001 
946 
(80.1%) 
457 
(68.4%) 
275 
(61.1%) <0.0001 
Prasugrel  Initial (n=5591) 
220 
(6.7%) 
36 
(1.6%) <0.0001 
12 
(1.0%) 
15 
(2.2%) 
9 
(2.0%) 0.0862 
 
Discharge 
(n=5587) 
207 
(6.3%) 
29 
(1.3%) <0.0001 
12 
(1.0%) 
9 
(1.3%) 
8 
(1.8%) 0.4532 
GP IIb/IIIa inhibitor (n=5591) 
455 
(13.9%) 
62 
(2.7%) <0.0001 
18 
(1.5%) 
28 
(4.2%) 
16 
(3.5%) 0.0013 
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Anticoagulants-parenteral  
(n=5591) 
2627 
(80.0%) 
1651 
(71.6%) <0.0001 
842 
(71.0%) 
495 
(74.0%) 
314 
(69.6%) 0.2275 
Anticoagulants-oral (n=5591) 
111 
(3.4%) 
166 
(7.2%) <0.0001 
98 
(8.3%) 
41 
(6.1%) 
27 
(6.0%) 0.1255 
Diagnostic/therapeutic 
procedures 
       
Echocardiography (n=5528) 
2497 
(76.8%) 
1711 
(75.1%) 0.1395 
885 
(75.8%) 
509 
(76.5%) 
317 
(71.1%) 0.0846 
LVEF <40% (n=5074) 
231 
(7.8%) 
222 
(10.5%) 0.0007 
135 
(12.5%) 
66 
(10.4%) 
21 
(5.2%) 0.0002 
Stress test (n=5567) 
28 
(0.9%) 
39 
(1.7%) 0.0046 
19 
(1.6%) 
14 
(2.1%) 
6 
(1.3%) 0.602 
Coronary angiography  
(n=5591) 
3285 
(100.0%) 
1120 
(48.6%) <0.0001 0 
669 
(100.0%) 
451 
(100.0%) <0.0001 
Multivessel disease  
(n=4239) 
1746 
(55.9%) 
441 
(39.6%) <0.0001 0 
441 
(66.6%) 0 <0.0001 
PCI (n=5591) 
 
3084 
(93.9%)       
CABG (n=5591) 
209 
(6.4%)       
Other discharge medications 
       Beta-blockers (n=5567) 
2848 1896 
<0.0001 
992 569 335 
<0.0001 
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(87.0%) (82.7%) (84.1%) (85.1%) (75.3%) 
ACE inhibitors/ARBs (n=5567) 
2427  
(74.1%) 
1719 
(75.0%) 0.4804 
901 
(76.4%) 
517 
(77.5%) 
301 
(67.5%) 0.0002 
Statins (n=5561) 
3083 
(94.3%) 
2012 
(87.8%) <0.0001 
1029 
(87.4%) 
617 
(92.4%) 
366 
(82.2%) <0.0001 
Diuretics (n=5559) 
651 
(19.9%) 
630 
(27.5%) <0.0001 
381 
(32.3%) 
173 
(25.9%) 
76 
(17.0%) <0.0001 
ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CABG, CAD, coronary artery disease; CAG, coronary 461 
angiography; CR, coronary revascularization; GP, glycoprotein; LVEF, left ventricular ejection fraction; MM, medically managed;  PCI, 462 
percutaneous coronary intervention. 463 
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Table 3. In-hospital and 2-year outcomes in non-ST-segment elevation acute coronary syndrome patients by 464 
management strategy  465 
  
  
Coronary 
Revascularization 
n=3285 
58.8% 
Medical 
Management 
n=2306 
41.2% 
P-Value 
(CR versus 
MM) 
Medical Management  
CAG- 
n=1186  
21.2% 
CAG+ CAD+ 
n=669 
12.0% 
CAG+ CAD- 
n=451 
8.1% 
P-Value 
Hospital outcomes        
 Myocardial infarction 75 (2.3%) 41 (1.8%) 0.1943 24 (2.0%) 11 (1.7%) 6 (1.3%) 0.61 
 Recurrent ischemia 127 (3.9%) 114 (5.0%) 0.0494 70 (6.0%) 29 (4.4%) 15 (3.3%) 0.0674 
 Heart failure 100 (3.0%) 188 (8.2%) <0.0001 139 (11.8%) 41 (6.1%) 8 (1.8%) <0.0001 
 Ventricular arrhythmia 63 (1.9%) 28 (1.2%) 0.0406 13 (1.1%) 7 (1.0%) 8 (1.8%) 0.4788 
 Atrial fibrillation/flutter 156 (4.8%) 156 (6.8%) 0.0011 102 (8.6%) 33 (4.9%) 21 (4.7%) 0.0014 
 Stroke 11 (0.3%) 4 (0.2%) 0.2509 2 (0.2%) 2 (0.3%) 0 (0.0%) 0.497 
 Bleeding 117 (3.6%) 37 (1.6%) <0.0001 13 (1.1%) 18 (2.7%) 6 (1.3%) 0.0281 
Clinically significant bleeding 86 (2..6%) 27 (1.2%) 0.9491 8 (0.7%) 14 (2.1%) 5 (1.1%) 0.4968 
2-year outcomes        
 Mortality 135 (4.4%) 233 (11.0%) <0.0001 158 (14.6%) 58 (9.3%) 17 (4.1%) <0.0001 
 CV mortality 59 (1.9%) 119 (5.7%) <0.0001 83 (7.9%) 31 (5.0%) 5 (1.2%) <0.0001 
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 Myocardial infarction 72 (2.4%) 80 (4.1%) 0.0009 47 (4.8%) 26 (4.4%) 7 (1.8%) 0.0421 
 Heart failure 29 (1.0%) 37 (1.9%) 0.0073 22 (2.2%) 12 (2.1%) 3 (0.8%) 0.202 
 Ventricular arrhythmia 7 (0.2%) 10 (0.5%) 0.1293 2 (0.2%) 7 (1.1%) 1 (0.2%) 0.043 
 Atrial fibrillation/flutter 10 (0.3%) 15 (0.7%) 0.0464 6 (0.6%) 4 (0.7%) 5 (1.2%) 0.4444 
 Stroke 20 (0.7%) 17 (0.9%) 0.4385 10 (1.0%) 4 (0.7%) 3 (0.8%) 0.7663 
 Bleeding 141 (4.6%) 68 (3.4%) 0.025 35 (3.5%) 24 (3.9%) 9 (2.2%) 0.2926 
 Clinically relevant bleed 63 (2.0%) 37 (1.8%) 0.5399 21 (2.1%) 14 (2.3%) 2 (0.5%) 0.1113 
CAD indicates coronary artery disease; CAG, coronary angiography; CR, coronary revascularization; CV, cardiovascular; LVEF, left ventricular 466 
ejection fraction; MM, medically managed.  467 
  
34 
Table 4. Hazard ratios for 2-year all-cause death in subgroups of medically 468 
managed versus revascularized NSTE-ACS patients by management 469 
strategy. Model adjusted for hospital type (regional, non-university general, 470 
university general, private) and geographical region, using a multi-level 471 
model to adjust for clustering 472 
Adjusted for Group 
Hazard ratio for death 
vs revascularized 
No adjustment CAG- 3.30 (2.54 to 4.27) 
 
CAG+ CAD+ 2.12 (1.54 to 2.92) 
 
CAG+ CAD- 0.86 (0.50 to 1.47) 
Age and sex CAG- 2.52 (1.94 to 3.27) 
 
CAG+ CAD+ 1.88 (1.36 to 2.58) 
 
CAG+ CAD- 0.96 (0.56 to 1.64) 
EPICOR risk score covariates CAG- 1.81 (1.23 to 2.65) 
 
CAG+ CAD+ 1.90 (1.23 to 2.95) 
CAG+ CAD- 0.68 (0.21 to 2.21) 
 473 
CAD, coronary artery disease; CAG, coronary angiography; NSTE-ACS, non ST-segment elevated 474 
acute coronary syndrome. 475 
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Figure 1. Distribution of EPICOR NSTE-ACS patients according to initial 476 
revascularization strategy and clinical pathways leading to medical 477 
management 478 
Abbreviations. CABG, coronary artery bypass graft; CAD, coronary artery disease; CAG, 479 
coronary angiography; NSTE-ACS, non-ST-segment elevation acute coronary syndromes; 480 
PCI, percutaneous coronary intervention 481 
 482 
Figure 2. Post-discharge event rates at 2 years according to management 483 
strategy: A) All-cause mortality; B) cardiovascular events; C) bleeding events 484 
Cardiovascular events included myocardial infarction, heart failure, arrhythmia, 485 
unstable angina, ischemic stroke, and transient ischemic attack. Bleeding events 486 
included all kinds of bleeds 487 
Abbreviations. CAD, coronary artery disease; CAG, coronary angiography; CR, coronary 488 
revascularization; MI, myocardial infarction; MM, medical management; TIA, transient 489 
ischemic attack; UA, unstable angina  490 
 491 
